Medincell SA is a France-based manufacturer of biological products and pharmaceutical preparations. The Company is focused on the development of therapeutic solutions with worldwide access. The Company works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations.
Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others..
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 75.4K |
| Three Month Average Volume | 1.6M |
| High Low | |
| Fifty-Two Week High | 18.74 EUR |
| Fifty-Two Week Low | 5.25 EUR |
| Fifty-Two Week High Date | 21 Aug 2024 |
| Fifty-Two Week Low Date | 01 Nov 2023 |
| Price and Volume | |
| Current Price | 18.08 EUR |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 15.46% |
| Thirteen Week Relative Price Change | 16.74% |
| Twenty-Six Week Relative Price Change | 109.03% |
| Fifty-Two Week Relative Price Change | 153.72% |
| Year-to-Date Relative Price Change | 147.72% |
| Price Change | |
| One Day Price Change | -3.00% |
| Thirteen Week Price Change | 11.60% |
| Twenty-Six Week Price Change | 100.89% |
| Five Day Price Change | 0.33% |
| Fifty-Two Week Price Change | 165.88% |
| Year-to-Date Price Change | 151.11% |
| Month-to-Date Price Change | -3.00% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -1.40428 EUR |
| Book Value Per Share (Most Recent Quarter) | -1.40428 EUR |
| Tangible Book Value Per Share (Last Fiscal Year) | -1.48856 EUR |
| Tangible Book Value Per Share (Most Recent Quarter) | -1.48856 EUR |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.67295 EUR |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.31781 EUR |
| Revenue Per Share (Trailing Twelve Months) | 0.31781 EUR |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 EUR |
| Dividend Per Share (Trailing Twelve Months) | 0 EUR |
| Dividend Per Share (5 Year) | -99999.99 EUR |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.88101 EUR |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.87536 EUR |
| Normalized (Last Fiscal Year) | -0.87797 EUR |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.88101 EUR |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.87536 EUR |
| Including Extraordinary Items (Last Fiscal Year) | -0.88101 EUR |
| Including Extraordinary Items (Trailing Twelve Months) | -0.87536 EUR |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.66939 EUR |
| Cash Per Share (Most Recent Quarter) | 0.66939 EUR |
| Cash Flow Per Share (Last Fiscal Year) | -0.8212 EUR |
| Cash Flow Per Share (Trailing Twelve Months) | -0.82053 EUR |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.46141 EUR |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -249 |
| Cash Flow Revenue (Trailing Twelve Months) | -145 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -276.24% |
| Pretax Margin (Last Fiscal Year) | -276.24% |
| Pretax Margin (5 Year) | -358.88% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 74.92% |
| Gross Margin (Trailing Twelve Months) | 74.92% |
| Gross Margin (5 Year) | 71.74% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -232.25% |
| Operating Margin (Trailing Twelve Months) | -232.25% |
| Operating Margin (5 Year) | -304.67% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -277.21% |
| Net Profit Margin (Trailing Twelve Months) | -277.21% |
| Net Profit Margin (5 Year) | -366.40% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -47.00% |
| Revenue Growth (3 Year) | 44.33% |
| Revenue Change (Trailing Twelve Months) | -8.67% |
| Revenue Per Share Growth | 30.63% |
| Revenue Growth (5 Year) | 3.33% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 9.57% |
| Total Debt (5 Year) | 16.88% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 19.53% |
| EPS Change (Trailing Twelve Months) | 31.10% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 39.5M |
| Net Debt (Last Fiscal Year) | 39.5M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 58 |
| Price to Sales (Trailing Twelve Months) | 58 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 2 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -13,113,000 |
| Free Cash Flow (Trailing Twelve Months) | -13,113,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -5 |
| Net Interest Coverage (Trailing Twelve Months) | -5 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -75.54% |
| Return on Assets (Trailing Twelve Months) | -75.54% |
| Return on Assets (5 Year) | -61.75% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -99,999.99% |
| Return on Investment (Trailing Twelve Months) | -99,999.99% |
| Return on Investment (5 Year) | -167.61% |